Federica Cappuccini, Richard Bryant, Emily Pollock, Lucy Carter, Clare Verrill, Julianne Hollidge, Ian Poulton, Megan Baker, Celia Mitton, Andrea Baines, Armin Meier, Guenter Schmidt, Richard Harrop, Andrew Protheroe, Ruth MacPherson, Steven Kennish, Susan Morgan, Selena Vigano, Pedro J Romero, Thomas Evans, James Catto, Freddie Hamdy, Adrian V S Hill, Irina Redchenko
BACKGROUND: Prostate cancer (PCa) has been under investigation as a target for antigen-specific immunotherapies in metastatic disease settings for the last two decades leading to a licensure of the first therapeutic cancer vaccine, Sipuleucel-T, in 2010. However, neither Sipuleucel-T nor other experimental PCa vaccines that emerged later induce strong T-cell immunity. METHODS: In this first-in-man study, VANCE, we evaluated a novel vaccination platform based on two replication-deficient viruses, chimpanzee adenovirus (ChAd) and MVA (Modified Vaccinia Ankara), targeting the oncofetal self-antigen 5T4 in early stage PCa...
June 2020: Journal for Immunotherapy of Cancer